News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Dense June 30 U.S. data slate, led by JOLTs and consumer confidence, may alter Fed policy and market rate expectations.
  • Amazon shifts Anthropic billing to token-based pricing next year but disputes claims it will materially raise model costs.
  • Taiwan prosecutors raided Super Micro offices probing alleged Nvidia chip diversion to China, sending the firm's shares down nearly 9% intraday.
  • France keeps national health emergency at highest level as another heatwave looms after roughly 1,000 excess deaths, raising public-health risks.
  • BEA methodology revisions are likely to trim May core PCE inflation, which could ease market pressure on Fed tightening expectations.
  • Natixis says the dollar rally has peaked and recommends structured options trades to short the greenback versus euro, yen and offshore yuan.

Latest Articles

Markets Enter Busy Week as Megacap Tech Earnings Take Center Stage

Markets Enter Busy Week as Megacap Tech Earnings Take Center Stage

U.S. equities closed mixed on Friday as the Nasdaq extended gains while the Dow slipped, with markets stabilizing after a thaw in geopolitical risks. Attention now shifts to fourth-quarter earnings from major technology companies and the Federal Reserve's policy decision, as investors assess whether heavy AI-related investment is beginning to produ…

H.C. Wainwright Lifts Scholar Rock Target to $58, Citing Strong KOL Feedback and Supply-Chain Workstreams

H.C. Wainwright Lifts Scholar Rock Target to $58, Citing Strong KOL Feedback and Supply-Chain Workstreams

H.C. Wainwright raised its price objective for Scholar Rock to $58 from $44 and kept a Buy recommendation after discussions with neurology key opinion leaders (KOLs) and review of the company’s launch-readiness plans for apitegromab. The firm cited positive physician feedback on recent FDA interactions, remediation efforts at manufacturing partners…

Needham Raises AppLovin to Buy, Sets $700 Target on Ecommerce Upside

Needham Raises AppLovin to Buy, Sets $700 Target on Ecommerce Upside

Needham upgraded AppLovin Corp (NASDAQ: APP) from Hold to Buy and set a $700 price target, implying roughly 33% upside from the stock's $524.41 level. The firm raised its 2026 ecommerce revenue forecast to $1.45 billion from $1.05 billion after additional analysis of AppLovin's ecommerce business and expects Q1 sequential growth as advertiser tract…

Once Upon a Farm launches IPO roadshow ahead of NYSE listing

Once Upon a Farm launches IPO roadshow ahead of NYSE listing

Once Upon a Farm has begun its investor roadshow for a planned initial public offering, filing to offer 10,997,209 shares of common stock and applying to list on the New York Stock Exchange under ticker OFRM. The offering includes primary shares, secondary shares from existing holders, an underwriter option, and an anticipated price range of $17 to…

Forgent Power Files U.S. IPO Plan to Raise Up to $1.62 Billion

Forgent Power Files U.S. IPO Plan to Raise Up to $1.62 Billion

Forgent Power has filed to offer Class A common stock in the United States, aiming to raise as much as $1.62 billion. The company plans to list on the New York Stock Exchange as FPS. The proposed offering totals 56 million shares, with specific allocations from the company and selling shareholders. Forgent reported substantial revenue growth year o…

Brazil's Current Account Deficit Holds Steady in 2025, Largely Buffered by FDI

Brazil's Current Account Deficit Holds Steady in 2025, Largely Buffered by FDI

Brazil closed 2025 with a current account deficit equal to 3.02% of GDP, almost unchanged from 3.03% in 2024, central bank figures show. The gap narrowed from an earlier widening to nearly 3.7% of GDP and remained mostly financed by foreign direct investment, which totaled 3.41% of GDP for the year. December data showed a narrower-than-expected cur…

Once Upon a Farm Seeks Up to $764.4 Million Valuation in U.S. IPO

Once Upon a Farm Seeks Up to $764.4 Million Valuation in U.S. IPO

Once Upon a Farm, the organic children’s food company co-founded by actor Jennifer Garner, filed to go public in the U.S., targeting a valuation of up to $764.4 million and seeking to raise nearly $209 million by offering about 11 million shares at $17 to $19 apiece. The company will list on the New York Stock Exchange under the symbol OFRM and has…

IonQ to Buy SkyWater in $1.8 Billion Cash-and-Stock Deal, Stocks Rise

IonQ to Buy SkyWater in $1.8 Billion Cash-and-Stock Deal, Stocks Rise

IonQ announced plans to acquire SkyWater Technology in a transaction valued at about $1.8 billion, a move that lifted IonQ and SkyWater shares. The deal, offering $15.00 cash and $20.00 in IonQ common stock per SkyWater share, is intended to combine IonQ’s quantum computing capabilities with SkyWater’s U.S.-based semiconductor manufacturing to form…

Santacruz Silver Shares Gain as Q4 Output Rises and Silver Tops $110/oz

Santacruz Silver Shares Gain as Q4 Output Rises and Silver Tops $110/oz

Santacruz Silver Mining Ltd. saw its stock climb 7% Monday after the company released fourth-quarter 2025 production figures and as silver prices pushed above $110 per ounce. Q4 consolidated output rose on a quarter-over-quarter basis driven by a notable recovery at the Bolívar mine following a May 2025 flooding event, while full-year 2025 producti…

BofA Securities Starts Coverage on Belite Bio With Buy Rating, $195 Target

BofA Securities Starts Coverage on Belite Bio With Buy Rating, $195 Target

BofA Securities opened coverage of Belite Bio, Inc. ADR (NASDAQ: BLTE) with a Buy rating and a $195 price target, implying roughly an 18% upside from the stock's last quoted price of $164.58. The firm emphasized the commercial opportunity for tinlarebant in Stargardt disease type 1 following positive Phase 3 data, while the company has also priced …